Lgr5 positive bi-potential hepatoblasts contribute to liver development and reside at the apex 31 of an embryonic liver progenitor pool. 32 33 34 35
To assess if these Lgr5+ cells are bona-fide hepatoblasts, we analysed their contribution to 141 the formation of both mature hepatocytes and cholangiocytes in the postnatal liver. To test 142 this, we induced Lgr5-CreERT2/R26R-TdTomato embryos at E9.5 and collected the livers 143 postnatally, over the course of a year ( Fig. 2A ). We detected TdTomato+ descendants of the 144 initially labelled E9.5-E10 Lgr5+ cells at all timepoints analysed (from 1 month up to 1 year 145 after birth) in all three functional zones of the liver (zones 1-3) ( Fig. 2B ). Importantly, we 146
found both hepatocytes as well as ductal cells (cholangiocytes), as descendants of the E9.5 147 Lgr5+ hepatoblasts. Remarkably, induction at later time points (E13.5) resulted in only 148 hepatocyte labelling at 1 month after birth, which indicated that, by E13.5, Lgr5+ embryonic 149 liver cells are already hepatocyte-fated hepatoblasts (Fig. S1A,B ). Of note, induction at 150 earlier timepoints (E7.5 and E8.5) did not result in any labelled progeny in the postnatal liver 151 ( Fig. S1A ), suggesting that embryonic Lgr5 exclusively marks liver progenitors after 152 specification and liver bud formation, but not definitive endoderm or foregut progenitors that 153 will contribute to the prospective liver tissue. No labelling was detected in non-tamoxifen 154 induced mice (Fig. S1C ). Collectively, our lineage tracing results demonstrate that Lgr5 is 155 indeed a bona-fide hepatoblast marker that identifies E9.5-E10 liver bud hepatic progenitors 156 with the capacity to give rise to adult hepatocytes and cholangiocytes. 157
Embryonic Lgr5+ cells are bona-fide bi-potential hepatoblasts in vivo 158 6 159
To date it has not been clear whether hepatoblasts are truly bipotential i.e. whether a single 160 hepatoblast gives rise to both cholangiocytes and hepatocytes, or conversely whether 161 hepatoblasts are unipotent and two types of hepatoblasts, progenitors for either hepatocyte or 162 cholangiocyte fates, coexist within the hepatoblast population. To formally assess whether 163 our E9.5-E10 Lgr5+ hepatoblasts are indeed bi-potential, we opted to use a multicolour 164 lineage tracing approach, where single cell clones are labelled with different colours in order 165
to discriminate the contribution of each individual clone to a given fate. Therefore, we used 166 lineage tracing with the R26R-Confetti reporter in combination with Lgr5-CreERT2, where 167 following clonal induction with tamoxifen at E9.5, Lgr5+ cells are labelled stochastically 168 with either RFP, YFP, GFP or CFP (Snippert et al., 2010)( Fig. 3A) . As expected, we detected 169 distinct clones labelled with one of the four fluorescent proteins at all time points analysed 170 (P0-P17) ( Fig. 3B ). 171 172 We recently showed that clonal fragmentation due to the expansion of the tissue during 173 development results in dispersion of clones throughout the tissue, hence imposing an 174 additional constraint on clonal fate studies during development (Rulands et al., 2018) . 175 Therefore, to ensure that we were scoring cells within individual clones, we opted to only 176 score as positive bi-potential clones, those clones in the portal tract where ductal cells and 177 hepatocytes were juxtaposed. We scored 70 individual clones, 81% of which were comprised 178 only of hepatocytes, whereas no cholangiocyte-only clones were found. Crucially, from all 179 the clones identified, 37% were identified near a portal tract and half of these (50%) 180 contained both labelled hepatocytes and cholangiocytes with the same confetti colour ( Fig.  181 3C,D)(Movie S1). As, expected, we also found clones formed of hepatocytes without 182 cholangiocytes throughout the liver in zones 2 and 3. These results are not explained by clone 183 merging, i.e., the probability of labelled cells with the same colour counted as a single clone 184 but originating from two recombination events, since our quantification of merging events 185 revealed a 1% probability (p=0.012) ( Fig. S2A,B ), indicating that from the 13 bi-potential 186 clones identified at least 11 clones are truly bi-potent. As before, no labelling was detected in 187 non-tamoxifen induced mice ( Fig. S2C ). 188
Therefore, the clonal analysis of Lgr5+ hepatoblasts demonstrates that Lgr5 marks a 189 population of E9.5-E10 hepatoblasts in which at least some are fully bi-potential at E9.5 time 190 point. 191 192 193 194 Lgr5+ embryonic liver cells grow into organoids in vitro and generate both ductal and 195 hepatocyte fated organoids in culture 196 197 In the adult liver of mouse (Huch et al., 2013b) and human (Huch et al., 2015) , single Lgr5+ 198 cells grown clonally into cholangiocyte liver organoids retain the bi-potential characteristics 199 of adult liver cholangiocyte progenitors, being able to self-duplicate while retaining the 200 capacity to differentiate into both hepatocytes and ductal cells in vitro. To assess whether our 201 Lgr5+ embryonic liver bi-potent hepatoblast would also be able to retain the self-renewing 202 7 and bi-potent differentiation characteristics in culture if grown into organoids, we sought to 203 establish liver organoids from Lgr5+ hepatoblasts and assess their bi-potential characteristics. 204 205 Recently, further optimization of our protocols to expand human adult liver cells (Huch et al., 206 2015) have facilitated the expansion of human embryonic (week 11-20 human gestation) 207 liver tissue as 3D organoid cultures (Hu et al., 2018) . However, the medium requirements to 208 establish mouse liver organoids from mouse embryonic bi-potent hepatoblasts have not yet 209 been reported. Hence, we first sought to establish culture conditions that would enable the 210 expansion of mouse organoid cultures from the embryonic liver. For that, we first opted to 211 use the entire liver tissue isolated from E10.5 mouse embryonic livers (without selection for 212 specific hepatoblast cells) and test several conditions in order to establish both cholangiocyte 213 and hepatocyte organoids from these early progenitors. We opted to use E10.5 instead of 214 E9.5 embryos for practical reasons; at E9.5 the prospective liver has not yet formed a clear 215 organ structure and therefore it was not possible to isolate only the liver, which resulted in 216 contamination from other foregut derived tissues, especially stomach (data not shown). To 217 establish cholangiocyte organoids from the embryonic liver we optimized our previously 218 published protocol to expand mouse adult liver organoids (Broutier et al., 2016; Huch et al., 219 2013b) by adding TGFb inhibitor and Forskolin (Fig. S3A ). In parallel, to establish 220 hepatocyte organoids, we adapted the recently published protocol from human embryonic 221 liver (Hu et al., 2018) by removing FGF7 during passaging (Fig. S3B ). Using these culture 222 conditions we could expand mouse embryonic liver organoids for up to 5 passages (3 months 223 in culture). 224
Next, we assessed whether single Lgr5+ cells isolated from E10.5 livers would retain their 225 ability to differentiate into either lineage in vitro when cultured in our optimized 226 cholangiocyte and hepatocyte media conditions. To this end, we first established a sorting 227 strategy that would enable isolation of pure populations of Lgr5+ E10.5 hepatoblasts, 228
utilising the Lgr5-GFP mouse line, where the eGFP reporter is knocked-in into the Lgr5 locus 229 (Barker et al., 2007) , combined with co-staining with anti-Liv2, which specifically labels 230 liver progenitors from E9.5-E13.5 (Nierhoff et al., 2005; Watanabe et al., 2002) . We 231 confirmed the hepatoblast nature of E10.5 Lgr5+ liver progenitors by co-staining with anti-232 Liv2 (Fig. 4A) . Given that the developing liver serves as the site of haematopoiesis from 233 E10.5 until the perinatal stage (Sasaki and Sonoda, 2000) , we used negative selection of the 234 hematopoietic marker CD45 and endothelial marker CD31 to limit contamination by non-235 liver progenitor cells. Embryonic livers were collected at E10.5-E12.5, enzymatically 236 digested and then fluorescence activated cell sorting (FACS) was used to isolate liver 237 progenitors and also Lgr5+ hepatoblasts (Fig. S4A ). The sorting strategy was sequentially 238 gated based on cell size, singlets, Liv2 + /CD31 -/CD45 -/Lgr5-GFP + . Sorted Lgr5 + cells were 239 embedded in Matrigel (as extracellular matrix) and cultured under our two optimized medium 240 conditions (Fig. 4B ). The morphology of structures generated was dependent on the culture 241 medium used. Addition of 'duct' medium, resulted in the generation of single-layer epithelial 242 spheres (Fig. 4C ). The duct-like morphology of embryonic organoids cultured with 'duct' 243 medium are reminiscent of adult mouse liver organoids (Huch et al., 2013b) . These cultures 244 expressed the classic cholangiocyte marker Krt19 (Fig.4E ). Conversely, Lgr5+ cells cultured 245 8 with 'hep' medium resulted in more compacted, dense and budding, bunch-of-grapes shape, 246 structures ( Fig. 4D) , that resembled the recently published human embryonic hepatocyte 247 organoids (Hu et al., 2018) . The hepatocyte nature of the embryonic cells grown with 'hep' 248 medium was confirmed by gene expression analysis, which showed high levels of Albumin in 249 the embryonic cells with very low levels of Krt19 (Fig. 4E ). Furthermore, 250 immunofluorescence analysis of the embryonic cells cultured with 'hep' medium confirmed 251 also their hepatocyte nature, with clear expression of the hepatocyte marker HNF4a and no 252 detection of the ductal marker EpCAM (Fig. 4F ). As expected, they also express Afp, a 253 classic hepatoblast marker ( Fig. 4G ), which is absent in our adult-derived organoids (Fig.  254 S3C). Therefore, these results confirm that Lgr5+ hepatoblasts retain self-renewal and 255 differentiation capacity, being capable of differentiating towards both cholangiocyte and 256 hepatocyte fates in vitro, when grown in our 3D organoid culture conditions. 257 258 scRNAseq identifies distinct heterogeneity within the hepatoblast population 259 260
To address whether all hepatoblasts express Lgr5 or whether instead Lgr5 is a marker of a 261 specific sub-population of bona-fide bipotential hepatoblasts, we performed single cell RNA 262 sequencing (scRNAseq) analysis on both Lgr5+ hepatoblasts and bulk embryonic liver cells 263 derived from either E10.5 or E13.5 livers. To isolate liver progenitors (Liv2+) and also Lgr5+ 264 hepatoblasts (Liv2+Lgr5+), we applied our established sorting strategy to E10.5 and E13.5 265 embryonic livers derived from Lgr5-GFP mice (Fig. 5A ). Therefore, sorted Liv2 + , CD31 -266 /CD45 -(Liv2+, bulk hepatoblast population) and Liv2 + /CD31 -/CD45 -/Lgr5-GFP + (Lgr5 + 267 hepatoblasts) were used for single cell RNA sequencing analysis based on the Smart-seq2 268
protocol (Picelli et al., 2014) . scRNAseq analysis was conducted on 943 sorted cells. 269
Following quality control, 653 cells were taken for further analysis. To reduce technical 270 variability between biological replicates, we applied batch effect correction by matching 271 mutual nearest neighbours. 272
To define embryonic liver progenitor populations, we performed dimensionality reduction 273 using t-distributed stochastic neighbour embedding (tSNE) analysis on all 653 cells ( Fig. 5B ).
274
This identified three distinct progenitor populations which were confirmed by Louvain 275
clustering. These three clusters signified biological differences, since each cluster contained 276 cells from each biological replicate. The biological differences were confirmed by the 277 expression of distinct marker genes (Fig. 5B, S4A and Supplementary dataset 1). The cell 278 type identity of each cluster was assigned based on examining the marker genes and 279 comparing them to publicly available gene expression patterns in human or mouse liver 280 (Broutier et al., 2017; Yang et al., 2017) . We found that the three clusters corresponded to 281 proliferating hepatoblasts (HB), hepatocyte-like progenitors (Hep) and cholangiocyte-like 282 progenitors (Chol), which express higher levels of representative markers. The hepatoblast 283 cluster contained Id3, Mdk and Gpc3, all described as hepatoblast markers (Su et al., 2017; 284 Yang et al., 2017) while the hepatocyte-like cluster presented Ttr, Alb, Apoa1, Apoa2 and C3 285 all known hepatocyte markers and the cholangiocyte-like cluster expressed the ductal cell 286
genes Car2, Cd44 and Bcl11a (Yang et al., 2017) ( Fig. 5B and Supplementary dataset 1_S1-287 S7). Of note, within the E10.5 cholangiocyte-like cluster we found two sub-clusters 288 9 (Supplementary dataset 1_S7). Although we found known cholangiocyte and hepatocyte 289 markers, new markers for these clusters were also revealed by the analysis (Fig. S5A and  290 Supplementary dataset 1_S1-S7). 291 292
To establish developmental trajectories between the different cells of the 3 clusters we 293 calculated diffusion maps and diffusion pseudotime. This analysis revealed a developmental 294 trajectory originating from the proliferating hepatoblast cluster which bifurcated towards 295 either the hepatocyte-like cluster or cholangiocyte-like cluster (Fig. 5C ). We found the 296 proliferating hepatoblast cluster contained a higher proportion of cells in G2M phase, 297
indicating an increased number of proliferative cells (Figs. 5C,S5B). When analysing the 298 lineage trajectories we took advantage of the Lgr5-GFP mouse line (Barker et al., 2007), 299 which enabled us to identify cells that expressed Lgr5 RNA via sequencing and compare 300 whether they were GFP positive from the FACS (Fig. 5D ,E). Since the GFP protein is more 301 stable than the transcript, we used the comparison between the Lgr5GFP sorted cells and the 302 cells expressing Lgr5 transcript as a proxy to identify the immediate descendants of Lgr5+ 303 cells in the scRNAseq population. Notably, most of the Lgr5+cells mapped to the hepatoblast 304 cluster, representing 2% of the total number of Liv2+ hepatoblasts at E10.5 ( Fig. S5C ). 305
Interestingly, we observed that as cells exit the hepatoblast cluster and become committed to 306 either of the two epithelial lineages Lgr5 transcript levels decrease ( Fig. 5D ). Many of these 307 transitioning cells ( Fig. 5E , black arrows) were negative for Lgr5 transcript but positive for 308
Lgr5GFP, indicating that these cells have only recently reduced Lgr5 levels as the GFP 309 protein has not yet degraded and can be considered immediate descendants of the Lgr5+ pool. 310
Interestingly, once cells have transitioned to the hepatocyte cluster Lgr5 is upregulated whilst 311
Lgr5 expression is not reinitiated in the cholangiocyte cluster. 312 313
Segregation of the data by embryonic stage shows that E10.5 cells contribute to the 314 proliferating hepatoblast cluster, the intermediate cells that are moving from the hepatoblast 315 towards the hepatocyte-like cluster, the hepatocyte-like cluster and cells located at the far end 316 of the cholangiocyte-like cluster ( Fig. 5F ). At E10.5, though, we find very few cells in the 317 transition between the proliferating hepatoblast and cholangiocyte-like cluster, however, 318 some of them were Lgr5GFP+ that had downregulated Lgr5 transcript, suggesting that they 319
were immediate descendants of the E10.5 Lgr5+ proliferating hepatoblast cluster cells. 320
Similarly, cells occupying this intermediate space were readily identified at E13.5, the 321 majority of which also appear to have recently downregulated Lgr5, again indicating that 322 they were immediate descendants of the Lgr5+ cells on the hepatoblast cluster. This implies 323 that the proliferating Lgr5+ hepatoblasts do indeed give rise to cholangiocytes at E10.5 but 324
with higher proportion at E13.5. Intriguingly, E13.5 cells (either Lgr5GFP+ or bulk) 325 significantly contributed to the cholangiocyte-like cluster, but we did not find E13.5 cells that 326 mapped to the hepatocyte cluster ( Fig. 5F ). This result was in striking disagreement with our 327 knowledge of liver development and our E13.5 lineage tracing results from the Lgr5-328
CreERT2 allele, which provides evidence that E13.5 Lgr5+ tracing resulted in labelling of 329 only hepatocytes ( Fig. S1B ), indicating that at E13.5, cells committed to a hepatocyte fate are 330 indeed present and express Lgr5. Our interpretation of this discrepancy between the lineage 331 tracing and the scRNAseq data is that the cells along the hepatocyte trajectory from E13.5 no 332 10 longer express the epitope for the anti-Liv2 antibody used during FACS, and thus were not 333 subject to sequencing. 334 335
Together, our scRNAseq analysis suggested that the E10.5 embryonic liver harbours distinct 336 sub-populations of liver progenitors that co-exist within the hepatoblast pool; a Lgr5+ sub-337 population that contributes to both hepatocyte and cholangiocytes and a previously 338
unrecognized sub-population of already cholangiocyte committed cells that has already 339 downregulated Lgr5 and started its specification to the cholangiocyte fate. 340 341
Lgr5 marks the apex cells within a E9.5 heterogenous hepatoblast pool 342 343
Our lineage tracing and single cell RNA sequencing data showed Lgr5 labels bi-potential 344 hepatoblasts which differentiate towards hepatocyte or cholangiocyte fates. This is indicative 345 of a hepatoblast hierarchy, and suggested Lgr5 as a potential marker of its apex. Quantifying 346 the number of tracing events as well as their contribution to the postnatal tissue provides 347 information on the potency and commitment of a given population in the developing tissue. 348
To determine whether Lgr5+ cells reside at the apex of a developmental hierarchy, we 349 reasoned that the cell composition of their clonal progeny must reflect quantitatively the 350 corresponding proportions in tissue. Therefore, we quantified the proportion of labelled 351 hepatocytes and cholangiocytes following lineage tracing from Lgr5-CreERT2 at E9.5 (Fig. 352 6A) and compared the proportions to the homeostatic distributions ( Fig. 6B ). We found that 353 the homeostatic proportion of hepatocytes and cholangiocytes in the mouse postnatal liver is 354 96.6 ± 0.6% and 3.4 ± 0.6%, respectively, ( Fig. S6 ); in agreement with previous reports in 355 rats (Blouin et al., 1977) . Remarkably, we found that lineage tracing with Lgr5-CreERT2 at 356 E9.5 resulted in labelled cells in which 96.7 ± 0.5% were hepatocytes and 3.3 ± 0.5% were 357 cholangiocytes, the same proportion of labelled hepatocytes and cholangiocytes as the 358 homeostatic liver ( Fig. 6C ). Therefore, although we cannot rigorously rule out the possible 359 contribution of a parallel Lgr5-cell lineage that produces differentiated progeny in tissue 360
proportions, these results strongly suggest that Lgr5 expression marks hepatoblasts that 361 constitute the apex of the differential hierarchy. 362 363
When analysing our single cell RNA sequencing data, we also found that at E10.5 there were 364 cholangiocyte-like cells that did not express Lgr5, suggesting that these were cholangiocyte-365 committed hepatoblasts even at this very early time point. To formally investigate whether 366 this was a genuine functional heterogeneity or was only reflecting transcriptional 367 heterogeneity at this time point we turned to a second lineage tracing strategy using an 368 ubiquitous and unbiased driver: the R26R-CreERT2. Lineage tracing from R26R-CreERT2 369 will label all cell types in the developing liver, including Lgr5+ and Lgr5-hepatoblasts, and 370 therefore labelled hepatocytes and cholangiocytes in postnatal livers will represent 371 descendants of any hepatoblasts labelled at E9.5 ( Fig. 6D ). Strikingly, we found a 372 significantly higher proportion of labelled cholangiocytes compared to the homeostatic 373
proportion when labelled with the unbiased R26R-CreERT2 allele at E9.5 (R26R-CreERT, 374 7.7 ± 1.9% cholangiocytes vs 3.3 ± 0.5% in homeostasis and with Lgr5-CreERT2) (Fig. 6C ). 375
These results were confirmed using multiple multicolour R26R-reporter alleles (R26R-376
Confetti and R26R-Rainbow). These findings are in agreement with our scRNAseq data, in 377 which we had observed that E10.5 hepatoblasts were already committed to a cholangiocyte 378 fate. 379 380
Interestingly, and in contrast to induction at E9.5, Cre induction from the R26R-CreERT2 381 allele at E13.5 gave rise to labelled hepatocytes and cholangiocytes in homeostatic 382 proportions ( Fig. 6C ), whilst lineage tracing from the Lgr5-CreERT2 allele at E13.5 gave rise 383 solely to labelled hepatocytes ( Fig. 6C ), suggesting that Lgr5+ cells lose their potency and 384 position in the hierarchy during the developmental progression. These results indicate that 385
hepatoblasts are not only heterogeneous in progenitor potential but their competence to 386 generate hepatocytes and cholangiocytes changes between E9.5 and E13.5. 387 388
In addition to the identity of labelled cells, the size of labelled clusters generated from the 389
Lgr5-CreERT2 and R26R-CreERT2 alleles was quantified as a proxy for the proliferative 390 potential of the initially labelled hepatoblast. We found that tracing with the Lgr5-CreERT2 391 allele at E9.5 gave rise to larger clusters of labelled cells than tracing with the R26R-392
CreERT2 allele ( Fig. 6E ,F). The larger cluster sizes from Lgr5+ hepatoblasts indicate that 393 these cells have a greater proliferative potential than the bulk hepatoblast population, again 394
suggestive of their position at the apex of the hepatoblast hierarchy. 395 396
Altogether combined, these results lead us to conclude that the E9.5 hepatoblast population is 397 indeed functionally heterogeneous, with Lgr5+ hepatoblasts residing at the apex of the E9.5 398 hierarchy and a population of non-Lgr5+ hepatoblasts exhibiting a previous unidentified early 399 commitment to the cholangiocyte fate. 400 401 402
Discussion

404
The Wnt target gene Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5) has 405 been described as a marker of stem cells in non-damaged, self-renewing tissues, such as the 406 intestine, stomach and hair follicles, as reviewed in (Barker et al., 2010) . In the adult liver, 407
Lgr5 is lowly expressed during homeostasis. However, upon damage Lgr5 becomes highly 408 upregulated in a subset of cells, which contribute to the regeneration of both, hepatocytes and 409 ductal cells. Similarly, Lgr5 is also upregulated in homeostatic liver ductal cells, when 410 cultured as self-renewing bi-potential liver organoids (Huch et al., 2013b) . Here we found 411 that Lgr5 marks a previously unknown bi-potent Lgr5+ population, which resides at the apex 412 of an E9.5 heterogenous hepatoblast pool. 413
To date, bi-potentiality of hepatoblasts has only been shown at the population level 414 (Yanagida et al., 2016) , however, at least in vivo, there has been no experimental proof 415 regarding bi-potentiality of individual hepatoblast cells. A recent report showed that a 416
labelled Foxa2+ definitive endoderm cell induced at E7.75 gives rise to cells moving towards 417 hepatocyte and cholangiocyte fates at E16.5, suggesting that at least, before hepatic 418 specification at E7.75, the definitive endoderm progenitors are multipotent (El Sebae et al., 419 2018) . Similarly, in vitro, Dlk+ embryonic liver cells at E14.5 were found to express markers 420 of both hepatocyte and cholangiocyte lineages (Tanimizu et al., 2003) , again suggestive of 421 the bi-potent nature of hepatoblast cells. However, formal proof of in vivo bi-potential 422 hepatoblasts has not yet been provided. Here, using lineage tracing with a multicolour 423
reporter we unequivocally demonstrate that E9.5 Lgr5+ hepatoblasts are indeed bi-potential 424 in vivo, as single clones consisting of cholangiocytes and hepatocytes are present at the portal 425 triad ( Fig. 3C ,D). It should be noted, though, that we also found clones formed of hepatocytes 426 without cholangiocytes throughout the liver; including in the portal region (zone 1). These 427
can have two possible explanations: either a subset of Lgr5+ cells is unipotent for hepatocyte 428 fate and others are bi-potent, or alternatively, all the Lgr5+ cells are bi-potent. The first option 429
(only a subset is bi-potent) implies that there is heterogeneity within the Lgr5+ population 430 regarding their potentiality. In that regard, our single cell data, where we find Lgr5+ cells in 431 both the hepatoblast and the hepatocyte clusters, suggest that this could indeed be a plausible 432
scenario. Alternatively, one could hypothesise that all the Lgr5+ cells are bi-potent but 433 depending on the external signals received according to the specific position of the original 434 Lgr5+ progenitor cell, they can differentiate into one or two cell types. This implies that 435 developmental stage and local environment could be critical in defining the final fate of a 436
given Lgr5+ hepatoblast. In that regard, the fact that embryonic Lgr5+ cells isolated by 437 FACS and cultured in vitro were sensitive to the growth factors present in the culture medium 438
and committed either to the cholangiocyte or hepatocyte lineage according to media 439 composition would argue in support of this latter argument ( Fig. 4 ). It is tempting to 440 speculate that by retaining Lgr5+ cells at defined positions during liver growth by 441 maintenance of a specific local environment, differentiation into cholangiocytes would occur 442 as daughter cells exited such a niche. This is consistent with current evidence of the 443 discontinuous growth of the liver ductal network as reviewed in (Ober and Lemaigre, 2018), 444 13 although there is at present no direct evidence for a role of Lgr5+ cells in directing liver 445 morphogenesis. 446
Interestingly, lineage tracing at E13.5 from the Lgr5-CreERT2 allele resulted in labelling of 447 only hepatocytes ( Fig. 6C ,S1B), while E13.5 lineage tracing from the R26R-CreERT2 allele 448 resulted in labelling of both, hepatocytes and ductal cells, in the homeostatic proportions 449 (96.4% and 3.6%, respectively). These results underline the continual shift in cell potency 450 and cell surface marker expression throughout development of the liver and are consistent 451 with other reports in which a single cell surface marker is not adequate to define a particular 452 cell type (hepatoblast, hepatocyte or cholangiocyte) throughout the entirety of liver 453 development (Tanaka et al., 2009) . Instead, a set of two or more cell surface markers will 454
have to be used to define each cell type at specific stages of development. In that regard we 455
found that while Liv2 is indeed a good marker of the hepatoblast pool at E10.5, it is not 456 appropriate to identify unbiased hepatoblasts at E13.5, as it seems to mark hepatoblasts 457 already biased towards the ductal fate. 458 459
In contrast to the widely accepted view that differentiation of hepatoblasts into 460 cholangiocytes occurs from E13.5 onwards (Gordillo et al., 2015) , our results provide the 461 functional demonstration that heterogeneity indeed already exists at E9.5 of liver 462 development. Our single cell RNA sequencing data shows that even as early as E10.5 there is 463 heterogeneity within the hepatoblast population, with some cells already moving towards 464 cholangiocyte or hepatocyte fates. We identify sub-populations of hepatoblasts that express 465
Lgr5 whilst other sub-populations do not. Further, some of these Lgr5-cells already express 466 markers of the cholangiocyte fate. In support of the scRNAseq data, our functional studies 467 which fate map E9.5 liver progenitors using lineage tracing from either Lgr5-CreERT2 or 468
R26R-CreERT2 demonstrate the existence of both Lgr5+ and Lgr5-hepatoblasts already at 469 E9.5 ( Fig. 6C ). Importantly, induction of lineage tracing at E9.5 using Lgr5-CreERT2, but 470 not R26R-CreERT2, resulted in labelled postnatal hepatocytes and cholangiocytes in 471 homeostatic proportions (97% hepatocytes vs 3% cholangiocytes), implying that Lgr5+ cells 472 functionally behave as a genuine bi-potent hepatoblast and are indeed at the apex of its 473 hepatoblast hierarchy. On the contrary, the unbiased R26R-CreERT2, gave rise to a higher 474
proportion of cholangiocytes at E9.5, compared to the homeostatic or Lgr5+ descendants, 475
arguing in favour of an already cholangiocyte-committed hepatoblast sub-population, 476 negative for Lgr5, in the E9.5 developing liver. This result suggests that E9.5 Lgr5+ cells are 477 at the apex of their hierarchy, i.e., are bi-potent and equipotent, and are able to give rise to 478 already lineage-restricted ductal progenitors that downregulate Lgr5 and expand in order to 479 contribute to the postnatal ductal pool. While our results demonstrate that Lgr5 expression 480 overlaps with the apex of an hepatoblast pool, they do not show functionally that Lgr5 481 expression defines the apex of the hepatoblast pool. Lgr5 expression could be subjected to 482 local environmental factors and just mark a subpopulation of cells that receives high Wnt 483
signalling. Then, one could speculate that Lgr5 negative hepatoblasts with the very same 484 potency as the Lgr5+ ones also reside at the apex of their own hierarchies. This implies that 485 populations of equally potent hepatoblasts, some of which express Lgr5 and are bi-potent, co-486 14 exist at this time point in development . If these additional hepatoblasts populations indeed  487 exist, what is their identity and bi-potentiality are still questions that remain to be addressed. 488 489
In summary, here, using a combination of lineage tracing, organoid cultures and scRNAseq 490 analysis we describe for the first time that the E9.5 hepatoblast pool is heterogeneous, not 491 only at the RNA, but also at the functional level. Within the different E9.5 hepatoblast sub-492 populations, we find that Lgr5 marks a previously unknown bi-potent Lgr5+ population, 493
which resides at the apex of its E9.5 hepatoblast hierarchy. Furthermore, we also describe a 494 previously un-identified sub-population of already cholangiocyte-committed cells that do not 495 express Lgr5. To our knowledge, this is the first report that recognizes the functional 496 heterogeneity of the E9.5 hepatoblast pool and the first demonstration that Lgr5 For quality control of cells, the following quality metrics were calculated for each cell: (1) 598 the percentage mitochondrial transcript reads, (2) the percentage of Spike-In reads, (3) the 599 total number of reads, and (4) the log10 transformed number of genes with at least one read. 600
Only cells with (1) less than 20% of mitochondrial reads, (2) less than 25% Spike-In reads 601
and (3) more than 100.000 reads were considered for downstream analysis. As the log10 602 transformed number of genes with at least one read (4) showed clear batch effects, the four 603 different thresholds 3.6, 3.5, 3.7, and 3.5 were applied to the four different sorts and only 604 cells exceeding these thresholds passed quality control. In total, 653 (69%) of 943 cells were 605 considered for downstream analysis. Because an initial principal component analysis revealed 606
batch effects between the biological replicates from experiments 1, 2 and 4 (group 1) on the 607 one hand and experiment 3 (group 2) on the other hand, batch correction between those two 608 groups was performed: For each group, only genes expressed in at least 3 cells were 609 considered. The counts in each group were normalised using size factors computed with the 610 scran (v1.8.4) function computeSumFactors (parameters: min_mean=1.0, size=seq(20, 100, 611 5)) (Lun et al., 2016) . For each group, highly variable genes were detected using the scanpy 612 function filter_genes_dispersion (parameter: max_mean=8) and the intersection of both gene 613 sets, which contained 1766 genes, was used for further analysis. Batch effects between the 614 two datasets were corrected by matching mutual nearest neighbours in the implementation of 615 mnnpy (v0. cluster against the union of the other two clusters as implemented in scanpy's 624 rank_genes_groups function. To define marker genes for the clusters at specific embryonic 625 stages, the cells were grouped according to cluster and stage and a Wilcoxon rank-sum test 626 was performed as described above. For the sub-clustering of the cholangiocyte-like cluster, a 627 principal component analysis was performed on those cells and then clustering was 628 performed as above with the resolution parameter set to 0.5. Differentially expressed genes 629 between the two resulting sub-clusters were detected as described above. The diffusion maps 630
were calculated using the scanpy function diffmap with the width of the Gaussian 631 connectivity kernel being implicitly determined by the distance to the 100 nearest neighbours 632
in the space of the 20 first principal components (Coifman et al., 2005; Haghverdi et al., 633 2015) . Diffusion pseudotime was calculated using scanpy's dpt function using the cell with 634 minimal diffusion component 1 as root cell (Haghverdi et al., 2016; Wolf et al., 2018a) .Cell 635 cycle phases were assigned using cyclone and the pre-trained mouse cycle markers contained 636 in the scran package (Scialdone et al., 2015) . Cells were classified as Lgr5 positive on the 637 transcript level if they had more than 10 reads of Lgr5. 638 639 640
3D culture of embryonic liver cells 641
Following isolation as described in isolation section above, the cells were pelleted at 400g 642 and seeded in Matrigel (BD Biosciences) and cultured either with the 'hep' protocol or 643
'ductal' protocol. The 'hep' method involves culturing for the first 3 days in Advanced 644 DMEM F12 supplemented with Penicillin/Streptomycin, Glutamax and HEPES (Gibco), 645 1xB27 (Gibco), 500 nM n-Acetylcysteine (Sigma), 10 mM Nicotinamide (Sigma), 100 ng/ml 646 Acknowledgements 661 662
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CreERT2;R26R-Confetti by breeding the Lgr5-ires-CreERT2 hom with the multicolour 905
Confetti reporter R26R-Confettihom which results in cells labelled in one of four colours 906 (RFP, YFP, mCFP, nGFP) when induced with 0.16mg/g tamoxifen at E9.5 (see 907 Supplementary Fig. 2 Magnification showing that the red clone contains both hepatocytes and ductal cells (white 918 arrows). (D) Pie-charts showing the total number of clones identified (n=70) and the fraction 919 of these that are located in the portal area (n=26). Note that from the total number of clones 920 found on the portal area, half of them (n=13) contained both hepatocytes and ductal cells of 921 the same colour. At the induction dose used, merging of clones of the same colour occurs 922 with a 1.2% probability (see Supplementary Fig. 2B ), which confirms that at least 11 of the 923 13 bi-potent clones identified arise from a single Lgr5+ cell, demonstrating that indeed Lgr5+ 924 cells are bi-potent at E9.5. Experiments were performed in n=3 embryos. and Lgr5-eGFP+) from E10.5-E13.5 Lgr5-EGFP-IRES-creERT2 embryos were obtained by 953 FACS sorting using the using the combination: Liv2+/CD31-/CD45-/Lgr5-eGFP+ cells as 954 26 described in Supplementary Fig.3 . Both, hepatoblasts cells (Liv2+, bulk hepatoblast pool) 955 and Lgr5+ hepatoblasts (Liv2+,eGFP+) were processed for scRNAseq analysis using 956
Smartseq2 protocol. Number of clusters identified and subsequent analysis was performed as 957 described in methods. (B) Clustering analysis (louvain clustering) of all the cells analysed 958 (653 sorted cells from E10.5 and E13.5 embryos) classified all the cells into 3 different 959 clusters: an hepatoblast cluster that exhibits features of hepatoblasts only and that we name 960 "early hepatoblast cluster" (HB, blue); an hepatoblast cluster with hepatocyte-like features 961
('Hep', green) and an hepatoblast cluster with cholangiocyte-like features ('Chol', orange). 962
Representative marker genes of each of these three clusters are shown: Id3 ('HB' cluster), 963
Ttr , grey; Liv2+Lgr5-eGFP+, green). Note that there are some Lgr5-eGFP+ cells that were sorted 976 as GFP+ but that have down-regulated the Lgr5-transcript (black arrows), indicating that 977 these are immediate descendants of the Lgr5+ cells. (F) Diffusion map showing the cells 978 segregate by time point (blue, E10.5; orange, E13.5). Note that cells sorted at E10.5 are found 979 in the proliferating hepatoblast cluster, in the cells moving towards the hepatocyte-like 980 cluster, the hepatocyte-like cluster and cells located in the cholangiocyte-like cluster. At 981 E13.5 the sorted cells map to the hepatoblast cluster, the cells moving towards the 982 cholangiocyte-like cluster and the cholangiocyte-like cluster. Sorted cells no longer map to 983 the hepatocyte cluster, which may indicate that hepatocyte-committed hepatoblasts do not 984 express the Liv2 epitope at E13.5. 985 986 Figure 6 : Lgr5+ hepatoblasts are at the apex of the hepatoblast hierarchy.
987
(A-E) Pregnant females from both, the Lgr5-Cre (Lgr5-CreERT2) and the ubiquitous Cre 988 (Rosa-CreERT2, R26RCre) were injected at E9.5 or E13.5 of gestation in order to lineage 989 trace the early hepatoblast pool. Livers were collected postnatally and assessed for the 990 contribution of the labelled descendants to the ductal and hepatocyte pools on the postnatal 991 liver. Clone composition, clone number and clone size were quantified. (A) Representative 992
images of Confetti-labelled descendants following tamoxifen induction to Lgr5-CreERT2; 993
R26Rconfetti mouse at E9.5 and liver collection at P17. Magnified area presents ductal cells 994
(Osteopontin+, purple) outlined in blue. (B) Schematic displaying the possible outcomes of 995 labelling proportions following lineage tracing of Lgr5+ cells at E9.5 depending on where 996
Lgr5+ cells are in the hepatoblast hierarchy (indicated with the blue arrow). If E9.5 Lgr5+ 997
hepatoblasts are at the apex of their hepatoblast hierarchy, it is expected that their 998 (A-D) To assess whether a single Lgr5+ hepatoblast is bi-potent, i.e., is able to give rise to both hepatocytes and ductal cells we generated the compound mouse Lgr5-ires-CreERT2;R26R-Confetti by breeding the Lgr5-ires-CreERT2 hom with the multicolour Confetti reporter R26R-Confetti hom which results in cells labelled in one of four colours (RFP, YFP, mCFP, nGFP) when induced with 0.16mg/g tamoxifen at E9.5 (see Supplementary Fig. 2 and Supplementary Dataset 2 for details). In this way we can identify individual clones to assess the bi-potentiality of individual hepatoblasts. (A) Schematic of experimental design. The scheme illustrates the two potential outcomes from the experiment; a single Lgr5+ hepatoblast (red circle) is bi-potent and gives rise to both hepatocytes (red squares) and ductal cells (red triangles) or, alternatively, single Lgr5+ hepatoblasts (blue and yellow circles) are unipotent and independently give rise to hepatocytes (blue squares) or ductal cells (yellow triangles). (B-C) Representative images of a P0 Lgr5-CreERT2+/-; R26R-Confetti+/-liver following induction at E9.5. Ductal cells were co-stained with OPN (blue, white arrows). Nuclei were stained with Hoechst. (B) Low power magnification of a liver section showing two labelled clones, a red clone and a yellow clone (white arrows). (C) Magnification showing that the red clone contains both hepatocytes and ductal cells (white arrows). (D) Pie-charts showing the total number of clones identified (n=70) and the fraction of these that are located in the portal area (n=26). Note that from the total number of clones found on the portal area, half of them (n=13) contained both hepatocytes and ductal cells of the same colour. At the induction dose used, merging of clones of the same colour occurs with a 1.2% probability (see Supplementary Fig. 2B ), which confirms that at least 11 of the 13 bi-potent clones identified arise from a single Lgr5+ cell, demonstrating that indeed Lgr5+ cells are bi-potent at E9.5. Experiments were performed in n=3 embryos. Supplementary Fig.3 ) were embedded in Matrigel and cultured in our optimized duct or hepatocyte (hep) mouse embryo liver medium as described in methods and Supplementary Figure 4A .5-E13.5 Lgr5-EGFP-IRES-creERT2 embryos were obtained by FACS sorting using the using the combination: Liv2+/CD31-/CD45-/Lgr5-eGFP+ cells as described in Supplementary Fig.3 . Both, hepatoblasts cells (Liv2+, bulk hepatoblast pool) and Lgr5+ hepatoblasts (Liv2+,eGFP+) were processed for scRNAseq analysis using Smartseq2 protocol. Number of clusters identified and subsequent analysis was performed as described in methods. (B) Clustering analysis (louvain clustering) of all the cells analysed (653 sorted cells from E10.5 and E13.5 embryos) classified all the cells into 3 different clusters: an hepatoblast cluster that exhibits features of hepatoblasts only and that we name "early hepatoblast cluster" (HB, blue); an hepatoblast cluster with hepatocyte-like features ('Hep', green) and an hepatoblast cluster with cholangiocyte-like features ('Chol', orange In the left panel, Lgr5 (blue arrow) is not at the apex, hence the homeostatic proportion is not achieved. On the contrary, in the right panel, Lgr5+ cells are at the apex, and that generates the homeostatic proportions. (C) Graph shows that 3.5% ± 0.5% of labelled epithelial cells following induction from Lgr5-creERT2 were ductal, which is equivalent to the homeostatic percentage of ductal cells in the postnatal liver (none Cre driver). In contrast, the percentage of labelled ductal cells using R26R-CreERT2 at E9.5 was significantly higher. At E13.5, lineage tracing from the Lgr5-CreERT2 allele resulted in no labelled ductal cells, whilst induction from the R26R-CreERT2 allele at E13.5 gave the same homeostatic proportion (mean±SEM, each data point represents an individual liver). Analysis of postnatal livers was conducted at timepoints P0-P30; later time points were not considered to prevent homeostatic cellular turnover confounding the data. **, p<0.01; ***, p<0.001. (D) Representative images of Confetti-labelled descendants following tamoxifen induction to R26R-CreERT2;R26Rconfetti mouse at E9.5 and with liver collection at P14. (E) Cumulative distribution of cluster size frequency at P14-P30, comparing labelled clusters derived from Lgr5+ cells (Lgr5-creERT2) and the bulk population (R26R-CreERT2) induced at E9.5 (mean±SEM, n≥6). Tracing from Lgr5+ cells results in larger clusters than tracing from the bulk population (F), suggesting that Lgr5+ cells have greater proliferative potential than the bulk population at E9.5 (mean±SEM). Representative image of one of the 2 merging events observed is shown. Example of a merging event between a CFP and GFP clone following induction at E9.5 in Lgr5-ires-creERT2+/-;R26R-Confetti+/-embryos. Scale bar, 100µm. Graph represents the proportion of bicolour-merging events identified in the 3 livers analysed (1.2% ± 1.0). Results represent mean ± SEM of the merging events found in the n=3 livers analysed (n=1, liver_1; n=1, liver_2, n=0, liver_3). (C-D) Tracing events from the R26R-confetti reporter are only in combination with the Lgr5-CreERT2 (C) or R26R-CreERT2 (D) driver are only detected upon tamoxifen administration and never found in non-induced mice. Supplementary Fig. 3: Lgr5+ hepatoblast sorting strategy. Lgr5-EGFP-IRES-CreERT2 het mice were breed and embryos collected at E10.5 of gestation. WT and Lgr5-EGFP-IRES-CreERT2 het littermate embryos were scored for the presence of eGFP in the cranial area. Then, embryos were split by genotype and liver tissues collected and processed for cell isolation and single cell dissociation. Cells were stained with the hepatoblast marker Liv2, the endothelial maker CD31 and pan-haemopoietic marker CD45 as described in methods. Sorted cells were obtained following a sequential gating strategy where cells were first gated by FSC vs SSC, then FSC vs Pulse with was used to identify singlets and then gated for Liv2+ (bulk hepatoblasts, Liv2 + CD31 -CD45 -) or Liv2+eGFP+ (Lgr5+ hepatoblasts, (Liv2 + CD31 -CD45 -GFP + (blue dashed box)). 
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